ONO exercises Fate CAR-T option in latest twist to partners' four-year deal

Paul Schloesser

Associate Editor

While some of the biggest players have jumped on CAR-T therapies and their potential in medicine, one of the newest developments in the space involves …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ONO exercises Fate CAR-T option in latest twist to partners' four-year deal

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

ONO ex­er­cis­es Fate CAR-T op­tion in lat­est twist to part­ner­s' four-year deal

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ONO exercises Fate CAR-T option in latest twist to partners' four-year deal